M
463.37
-29.74 (-6.03%)
| Penutupan Terdahulu | 493.11 |
| Buka | 486.26 |
| Jumlah Dagangan | 580,322 |
| Purata Dagangan (3B) | 352,206 |
| Modal Pasaran | 10,683,300,864 |
| Harga / Jualan (P/S) | 10.88 |
| Harga / Buku (P/B) | 23.06 |
| Julat 52 Minggu |
| Margin Keuntungan | -123.38% |
| Margin Operasi (TTM) | -57.79% |
| EPS Cair (TTM) | -17.83 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.85% |
| Nisbah Semasa (MRQ) | 5.91 |
| Aliran Tunai Operasi (OCF TTM) | -395.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -274.11 M |
| Pulangan Atas Aset (ROA TTM) | -25.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Madrigal Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 7.73% |
| % Dimiliki oleh Institusi | 108.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 31 Mar 2026 | 1,993,687 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 1,818,181 |
| Paulson & Co. Inc. | 31 Mar 2026 | 1,392,188 |
| William Blair Investment Management, Llc | 31 Mar 2026 | 340,519 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SIBOLD WILLIAM JOHN | - | 535.69 | -2,500 | -1,339,225 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,339,225 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 535.69 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SIBOLD WILLIAM JOHN | Pegawai | 20 Jul 2026 | Jual (-) | 2,500 | 535.69 | 1,339,225 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |